FOLH1 and prostate carcinoma: Given the broad interest in the development of P13K inhibitors in cancer, PSMA-targeted imaging, e.g., [68Ga]-PMSA-HEBD-CC, may allow for the selection of those prostate carcinoma patients most likely to benefit from such novel therapeutic agents.